Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · May 18, 2024

Reduced-Dose Azacitidine Plus Venetoclax as Maintenance Therapy for AML After Intensive or Low-Intensity Induction

The Lancet Haematology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

The Lancet Haematology
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Lancet Haematol 2024 Apr 01;11(4)e287-e298, A Bazinet, H Kantarjian, A Bataller, N Pemmaraju, G Borthakur, K Chien, Y Alvarado, P Bose, E Jabbour, M Yilmaz, C DiNardo, G Issa, G Montalban-Bravo, N Short, K Sasaki, D Bull-Linderman, N Daver, G Garcia-Manero, F Ravandi, T Kadia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated